The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the
pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents …

Alzheimer disease (AD) research community. On one side, adherents to the amyloid
hypothesis, an evolving body of evidence that abnormal accumulation and aggregation of β …

Abstract Development of disease‐modifying treatments for Alzheimer's disease (AD) has
been challenging, with no drugs approved to date. The failures of several amyloid‐targeted …

In the march towards disease-modifying treatments for Alzheimer disease, immunotherapy
with antibodies against amyloid-β protein is furthest along in human trials. The news that …

Background. Aducanumab, a new monoclonal antibody that targets β‐amyloid aggregates,
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …

Aducanumab is a monoclonal antibody targeting amyloid beta protein (Aß), a defining
feature of the biology of Alzheimer's disease (AD)[1]. Laboratory studies showed high affinity …

Abstract Introduction Aducanumab (BIIB037), a human monoclonal antibody selective for
aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for …

When the US Food and Drug Administration used the accelerated approval process to
authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD) …

Background Aducanumab is a human monoclonal antibody that selectively targets
aggregated forms of Aβ, including soluble oligomers and insoluble fibrils. EMERGE and …

Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …